Across TCGA pan-cancer cohorts, RPL23P11 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL23P11’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL23P11 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL23P11 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BRCA, COAD, and HNSC are the cancer types where RPL23P11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23P11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.038	.011	2	view →
COAD	All	All	+0.076	.047	1	view →
HNSC	All	All	+0.037	.048	1	view →
KIRC	All	All	+0.021	.036	1	view →
LIHC	All	All	+0.018	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL23P11 RNA expression & survival · all RPL23P11 data types